40 citations
,
November 2017 in “International journal of nanomedicine” In this study, the researchers reported that chloramphenicol-loaded liposomes, particularly those incorporating deoxycholic acid, enhanced follicular uptake and showed strong antibacterial activity against methicillin-resistant Staphylococcus aureus, offering potential for treating MRSA-infected skin conditions with good skin biocompatibility and minimal toxicity.
May 2018 in “Digital ProScholar Media eBooks” This study evaluated the antimicrobial activity of a newly synthesized fluoroquinolone against Staphylococcus, Streptococcus, and Escherichia coli strains. The researchers compared results from the microdilution technique and agar disk diffusion method to EUCAST's recommended breakpoint values, building on promising in silico molecular docking tests.
February 2023 in “Reactions Weekly” May 2024 in “News Digital Object Group”
3 citations
,
March 2019 in “Journal of Pigmentary Disorders” This presentation highlighted future directions in acne care, emphasizing the roles of topical and oral antibiotics, as well as skin microbiome studies. It also described how clascoterone targets androgen receptors in hair follicles and sebaceous glands to reduce sebum production.
March 2026 in “Frontiers in Bioscience-Elite” This study found that duloxetine and escitalopram exhibited broad-spectrum antimicrobial activity, while buspirone had selective effects, and finasteride disrupted yeast virulence traits, suggesting these drugs could be repurposed as antimicrobial therapies.
3 citations
,
November 2017 in “International Journal of Pharmacy and Pharmaceutical Sciences” This study identified new oxidative derivatives of finasteride, including a newly discovered metabolite, by using the fungus Macrophomina phaseolina.
This study reported that clascoterone cream reduced inflammatory and noninflammatory acne lesions in a trial with 1440 white males and non-pregnant females, showing it was well tolerated in these participants.
11 citations
,
November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” This study observed that early treatment with azithromycin and either nitazoxanide, ivermectin, or hydroxychloroquine in COVID-19 patients may reduce viral shedding, symptom duration, and respiratory complications compared to untreated patients.
6 citations
,
August 2024 in “The Journal of Dermatology” In this study, ozenoxacin was found to inhibit sebum production in insulin- and 5α-DHT-differentiated hamster sebocytes in a dose-dependent manner, suggesting potential benefits in acne management by combining antimicrobial activity against C. acnes with reduced sebum production.
22 citations
,
August 2020 in “Actas Dermo-Sifiliográficas” This review discusses the properties and applications of doxycycline in dermatology and reports no new clinical results, emphasizing its potential for treating various dermatological conditions.
109 citations
,
March 2011 in “Journal of controlled release” This study found that econazole nitrate delivered via MPEG-dihexPLA micelles significantly increased skin deposition compared to Pevaryl® cream, potentially enhancing drug bioavailability and clinical efficacy.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
11 citations
,
January 2000 in “The Journal of Steroid Biochemistry and Molecular Biology” This study found that LY320236 is a competitive inhibitor of type I and a non-competitive inhibitor of type II steroid 5alpha-reductase, indicating its potential as a dual inhibitor with differing modes of activity.
This study found that supraphysiological and physiological androgen levels inhibited U937 macrophages' phagocytosis of MRSA compared to untreated controls, but AR antagonism reversed this effect, suggesting targeting AR or using 5alpha-reductase inhibitors might aid bacterial clearance in elderly males' chronic wounds.
February 2026 in “Toxicology Letters” This study used an in silico/in vitro approach to identify potential inhibitors of the enzyme SRD5A2, finding that the androgen receptor modulator MK-0773 is a moderate inhibitor, although it does not act as a covalent inhibitor like finasteride.
1 citations
,
July 1988 in “JAMA” This report describes a case of pneumonitis caused by metronidazole in a 42-year-old woman hospitalized with no known drug hypersensitivity.
2 citations
,
January 2012 in “PubMed” This study found that mycophenolate mofetil is effective for both induction and maintenance therapy in children with severe lupus nephritis, significantly improving proteinuria and antibody levels, without renal flares during maintenance.
April 2017 in “Journal of Investigative Dermatology” This study suggests that sirolimus and propranolol may reduce abnormal lymphatic endothelial cell proliferation in lymphatic malformations, potentially improving vessel function and patient outcomes.
10 citations
,
April 2000 in “Archives of Oral Biology” Minocycline may cause hair loss by increasing DHT levels, but finasteride can help counteract this effect.
17 citations
,
June 2020 in “British Journal of Dermatology” This study observed that oral mTOR inhibitors frequently cause dermatological side effects, such as mouth ulcers and acneiform eruptions, but these rarely require stopping the treatment.
19 citations
,
December 2016 in “The journal of pharmacology and experimental therapeutics/The Journal of pharmacology and experimental therapeutics” This study found that multiple ion channel modulators, used here at clinical concentrations, increased intracellular calcium release in prostate and breast cancer cell lines.
28 citations
,
September 2000 in “Journal of Medicinal Chemistry” This study identified novel compounds as selective inhibitors of the type 1 isoenzyme of 5α-reductase, displaying promising potential for treating DHT-dependent disorders such as acne and androgenic alopecia.
89 citations
,
February 1993 in “Journal of Medicinal Chemistry” This research article focuses on nonsteroidal inhibitors of human type I steroid 5-alpha-reductase but reports no new results.
2 citations
,
May 2025 in “Frontiers in Immunology” This study explores the regulatory effects of ursolic acid on macrophage function and suggests potential for developing new anti-inflammatory and immunomodulatory drugs, though further research is needed for clinical applications.
137 citations
,
December 2006 in “Arthritis Research & Therapy” This study found that mycophenolate mofetil was associated with higher response rates and lower rates of serious side effects, including a lower mortality rate, compared to cyclophosphamide in lupus nephritis treatment.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” This review discusses the pharmacological profile of teriflunomide for treating relapsing multiple sclerosis, highlighting its safety and effectiveness in reducing relapses and slowing disability progression, though direct comparisons with other oral medications are lacking.
2 citations
,
November 2025 in “British Journal of Pharmacology” In this study, researchers validated a computational workflow for repurposing non-antibacterial drugs as antibacterial agents and highlighted daprodustat, combined with an efflux pump inhibitor, as a promising strategy against bacterial pathogens.
6 citations
,
November 2023 in “Chinese Medicine” This study found that Xinyang Tablet may improve cardiac function in LPS-induced sepsis-induced myocardial dysfunction by modulating macrophage polarization and autophagy through affecting LncSICRNT1 and TRAF6 expression.
86 citations
,
June 2018 in “Cochrane library” This review update suggests that mycophenolate mofetil may increase complete disease remission in proliferative lupus nephritis compared to intravenous cyclophosphamide, but with low certainty of evidence.